Ranbaxy Records $568 Million Loss For DoJ Penalty; Sees More Predictability In U.S. Business
This article was originally published in The Pink Sheet Daily
Executive Summary
India’s Ranbaxy has reported mixed results as it tops $2 billion in sales but suffers $568 million in losses from a U.S. consent decree penalty.